A High Content Imaging Assay for Identification of Botulinum Neurotoxin InhibitorsKrishna P. Kota 1,6, Veronica Soloveva 2,6,7, Laura M. Wanner 3,6, Glenn Gomba 4,6, Erkan Kiris 3,5,6, Rekha G. Panchal 6, Christopher D. Kane 2,6,7, Sina Bavari 6
1Perkin Elmer Inc., 2Henry M. Jackson Foundation, 3The Geneva Foundation, 4ORISE, 5Frederick National Laboratory for Cancer Research, 6Division of Molecular and Translational Sciences, US Army Medical Research Institute of Infectious Diseases, 7DoD Biotechnology High Performance Computing Software Applications Institute (BHSAI), Telemedicine and Advanced Technology Research Center (TATRC), US Army Medical Research and Materiel Command (USAMRMC)
Botulinum neurotoxin is one of the most potent toxins among Category-A biothreat agents, yet a post-exposure therapeutic is not available. The high content imaging approach is a powerful methodology for identifying novel inhibitors as it enables multiparameter screening using biologically relevant motor neurons, the primary target of this toxin.
